MannKind Showcases Efficacy, Safety, and Mealtime Control Data from Recent Pediatric and Adult Studies of Afrezza® at the ATTD Conference, March 19-22
March 10, 2025 06:05 ET
|
MannKind
MannKind Showcases Efficacy, Safety, and Mealtime Control Data from Recent Pediatric and Adult Studies of Afrezza® at the ATTD Conference, March 19-22
Cholesterol Test Market Size is Expected to Reach USD 16.10 Billion by 2033, Growing at a CAGR of 7.4%: Straits Research
March 06, 2025 09:20 ET
|
Straits Research Private Limited - Garner Insights
New York, United States, March 06, 2025 (GLOBE NEWSWIRE) -- A cholesterol test, a lipid panel, or a lipid profile is a blood test used to measure cholesterol levels and other fats in the blood. It...
Glucagon-Like Peptide-1 Receptor (GLP-1R) Agonists in Type 2 Diabetes and Obesity: 68-Market Analysis and Sales Forecast 2023-2033
February 19, 2025 10:09 ET
|
Research and Markets
Dublin, Feb. 19, 2025 (GLOBE NEWSWIRE) -- The "Glucagon-Like Peptide-1 Receptor (GLP-1R) Agonists in Type 2 Diabetes and Obesity: 68-Market Analysis and Sales Forecast" report has been added to ...
Inaugural Eye Health Summit Empowers Public with Integrative Vision Care Insights from Leading Experts
February 19, 2025 09:00 ET
|
The Eye Health Summit
The Eye Health Summit, a new global patient-centered event dedicated to integrative eye health, will take place May 1–7 as a free hybrid event.
UMeWorld Limited Announces Groundbreaking Study Published in the Journal of Lipid Research, Highlighting the Benefits of Low Triglyceride DAGola Cooking Oil for Athletes
February 18, 2025 08:00 ET
|
UMeWorld Limited
UMeWorld announces groundbreaking study on DAGola oil, showing benefits in reducing uric acid and triglycerides for athletes, supporting long-term health.
Rani Therapeutics Announces Preclinical Data Demonstrating Successful Oral Delivery of Semaglutide via RaniPill® HC
February 05, 2025 16:05 ET
|
Rani Therapeutics, LLC
- Oral semaglutide administered via the RaniPill® HC (RT-116) demonstrated comparable bioavailability, pharmacokinetics and weight loss to subcutaneous administration - - RT-116 was well tolerated...
Type 1 Diabetes 68-Market Analysis and Sales Forecasts 2023-2025 & 2033 Featuring Abbvie, Allergan, Eli Lilly, Pfizer, Sanofi, Novo Nordisk, vTv Therapeutics, Johnson & Johnson, and Adocia
February 04, 2025 09:20 ET
|
Research and Markets
Dublin, Feb. 04, 2025 (GLOBE NEWSWIRE) -- The "Type 1 Diabetes: 68-Market Analysis and Sales Forecast" report has been added to ResearchAndMarkets.com's offering.This report covers the 68...
SAB BIO to Participate in Upcoming Investor Conferences
January 31, 2025 07:00 ET
|
SAB Biotherapeutics, Inc.
MIAMI, Jan. 31, 2025 (GLOBE NEWSWIRE) -- SAB BIO (Nasdaq: SABS), (“SAB BIO” or the “Company”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing...
Free diabetes prevention program helps people lower their risk and stay healthy
January 28, 2025 11:23 ET
|
YMCA of Northern Alberta
YMCA offers a free diabetes prevention program. Participants can learn more at our wellness day on January 29 at Castle Downs Family YMCA.
SAB BIO Announces Positive Topline Phase 1 Clinical Results with Potentially Disease-Modifying T1D Therapy SAB-142
January 28, 2025 07:00 ET
|
SAB Biotherapeutics, Inc.
SAB BIO Announces Positive Topline Phase 1 Clinical Results with Potentially Disease-Modifying T1D Therapy SAB-142